Want to see TSE:OTC full AI Analyst Report?
Ocumetics Technology Corp (OTC) AI Stock Analysis
Ocumetics Technology Corp
(TSXV:OTC)
The overall score is low primarily because the company remains pre-revenue with deepening losses, negative equity, shrinking assets, and persistent cash burn, creating significant financial risk and reliance on fresh capital. Secondary pressure comes from an unappealing valuation profile given the negative P/E and lack of dividend data, while the technical picture is only moderately weak, suggesting some potential near-term stabilization but not enough to offset the underlying financial and valuation challenges.
Ocumetics Technology Corp (OTC) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 52.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 21.34K
- Price to Earnings (P/E)
- -6.6
- Beta (1Y)
- 0.86
- Revenue Growth
- ―
- EPS Growth
- -90.61%
- Country
- Canada
- Employees
- 5
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Ocumetics Technology Corp Business Overview & Revenue Model
Company Description
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the e...
Ocumetics Technology Corp Financial Statement Overview
Summary
Financial performance is very weak, with zero revenue, widening operating and net losses, negative shareholders’ equity, shrinking assets, and consistently negative operating and free cash flow, leaving the company highly dependent on ongoing external financing despite modest balance sheet support from debenture conversions and equity financings.
Income Statement
22NegativeBalance Sheet
12Very NegativeCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -156.19K | -149.37K | -134.30K | -117.62K | -102.21K | -96.18K |
| EBITDA | -4.33M | -3.87M | -2.29M | -3.50M | -2.09M | -3.43M |
| Net Income | -7.57M | -5.37M | -3.02M | -3.64M | -2.22M | -598.19K |
Balance Sheet | ||||||
| Total Assets | 748.53K | 1.90M | 2.32M | 1.04M | 1.37M | 825.25K |
| Cash, Cash Equivalents and Short-Term Investments | 88.74K | 464.04K | 1.57M | 235.83K | 602.09K | 83.90K |
| Total Debt | 4.31M | 5.30M | 3.95M | 321.64K | 292.34K | 0 |
| Total Liabilities | 5.14M | 5.85M | 4.26M | 945.33K | 536.45K | 1.10M |
| Stockholders Equity | -4.39M | -3.94M | -1.94M | 91.10K | 837.40K | -270.50K |
Cash Flow | ||||||
| Free Cash Flow | -2.70M | -3.49M | -2.51M | -2.19M | -1.69M | -213.63K |
| Operating Cash Flow | -2.66M | -3.37M | -2.43M | -2.05M | -1.62M | -89.13K |
| Investing Cash Flow | -103.94K | 1.25M | -1.46M | -142.17K | -66.82K | -214.92K |
| Financing Cash Flow | 2.44M | 2.38M | 3.85M | 1.82M | 444.35K | 387.11K |
Ocumetics Technology Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OTC, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.43, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 37.09 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OTC.
Ocumetics Technology Corp Peers Comparison
Overall Rating
TSE:COV70Outperform
TSE:ASG47Neutral
TSE:VPT46Neutral- TSE:OTC43Neutral
TSE:PINK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:COV | 70Outperform | CAD 122.35M | 28.16 | 15.04% | ― | 4.11% | 88.39% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:ASG | 47Neutral | CAD 8.98M | -5.36 | -34.32% | ― | -5.42% | -5.37% |
| TSE:VPT | 46Neutral | CAD 15.43M | -6.13 | 56.40% | ― | 89.06% | 37.62% |
| TSE:OTC | 43Neutral | CAD 56.15M | -6.61 | 175.10% | ― | ― | -90.61% |
| TSE:PINK | 38Underperform | CAD 27.62M | -1.41 | -303.05% | ― | 35.27% | 58.34% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:OTC | Ocumetics Technology Corp | 0.39 | -0.71 | -64.55% | |
| TSE:ASG | Aurora Spine | 0.12 | -0.17 | -58.93% | |
| TSE:COV | Covalon Technologies | 4.43 | 2.33 | 110.95% | |
| TSE:PINK | Perimeter Medical Imaging Ai Inc | 0.18 | -0.05 | -23.40% | |
| TSE:VPT | VentriPoint Diagnostics | 0.08 | -0.02 | -20.00% | |
| TSE:CNVI | Conavi Medical Corp. | 0.11 | -0.54 | -82.62% |
Ocumetics Technology Corp Corporate Events
Ocumetics Strengthens Board Leadership Amid Push to Fund Vision-Tech Trials
PositiveOcumetics Technology Corp. has reshaped its board leadership, appointing venture capitalist and fintech entrepreneur Sandi Gilbert as a director and elevating President and CEO Dean Burns to chairman. Gilbert’s deep capital markets experience,...
Ocumetics Marks Key 12-Month Milestone in First-in-Human Lens Trial
PositiveOcumetics Technology Corp. reported that Group One patients in its first-in-human clinical trial of the Ocumetics accommodating intraocular lens have reached the key 12-month follow-up milestone, with detailed results to be disclosed later. The compa...
Ocumetics Advances Next-Gen Intraocular Lens Trials With Group Two Recruitment
PositiveOcumetics Technology Corp. has begun recruiting patients in Mexico City for Group Two of its human clinical study of the next-generation Ocumetics accommodating intraocular lens, with surgeries targeted for fall 2026. This phase will move beyond the...
Ocumetics Readies Next-Gen Intraocular Lens for Second Human Trials
PositiveOcumetics Technology Corp. has completed manufacturing of its next-generation solid state accommodating intraocular lenses, clearing the way for Group Two first-in-human clinical surgeries in Mexico City. The lenses, produced in Germany and set to sh...
Ocumetics Completes Final Tranche of $3.1 Million Private Placement to Advance Lens Trials
PositiveOcumetics Technology Corp. has completed the third and final tranche of its previously announced unit private placement. In this last tranche, the company issued 405,000 units at $0.40 per unit, each comprising one common share and one warrant, bring...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026